Bioxytran, Inc. (BIXT)
OTCMKTS
· Delayed Price · Currency is USD
0.1497
+0.0147 (10.89%)
May 21, 2025, 2:20 PM EDT
Bioxytran Employees
Bioxytran had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
12.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,914 |
Bioxytran News
- 6 hours ago - Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission - GlobeNewsWire
- 9 days ago - Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M - GlobeNewsWire
- 5 weeks ago - Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - GlobeNewsWire
- 2 months ago - Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens - GlobeNewsWire
- 2 months ago - Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions - GlobeNewsWire
- 4 months ago - Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs - GlobeNewsWire
- 8 months ago - Bioxytran's Medical Breakthrough in Fighting All Viruses - Accesswire
- 9 months ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire